| Name | Title | Contact Details |
|---|
The Leader's Board is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New Mexico Cancer Care is a Santa Fe, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
E P Radiological Svc is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 1969, AvMed began in South Florida as Aviation Medicine to serve the growing airline industry by providing pilot physicals. Today, with offices in every major metropolitan area of the state, AvMed aims to inspire its membership of 300,000 Floridians to “Embrace better health.” AvMed provides Medicare Advantage coverage in Broward and Miami-Dade counties, Individual and Family coverage in Broward, Miami-Dade, and Palm Beach counties and Commercial coverage in more than 30 counties across the state. Major employer clients have been partners for decades, a testament to AvMed`s culture of service, which consistenly ranks above statewide peers.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.